Funding Announcements

"Cellular machinery still rejects these therapies, limiting long-term effectiveness and forcing costly, unsafe doses. Our platform introduces a vital shift from trial-and-error screening to repeatable, engineering-driven DNA design,"

"When I found an error in my own tax return while testing the platform, I was shocked – I’d paid for professional help, I work in finance, and I was still left wondering whether everything had actually been done correctly. That simply shouldn’t still be the case in 2026,"

"WhatsApp is about to become the default commerce channel for businesses. OpenAI wants those conversations to happen in ChatGPT and Google wants them in Search, but customers already spend their time on WhatsApp. We built Wassist so brands can own those conversations themselves,"

"Difficulty taking tablets is a common problem in paediatrics but extends to adults experiencing swallow impairment, including those suffering from serious conditions such as stroke, dementia and some forms of cancer. Our liquid products are effective and stable at room temperature with a long shelf life, improving medication adherence, dosage accuracy and convenience for the NHS, patients, and caregivers. We are thrilled to receive this investment, which will help us make a significant impact on the global pharmaceutical landscape."

"Most AI startups are building better tools. At Atheni, we are building master craftspeople. Organisations can tell you how many people have access to AI, but not whether anyone is using it to think more clearly, challenge an assumption or do work they couldn’t do before. That is the gap. Atheni measures it and shows organisations how to close it."